YIFAN PHARMACEUTICAL(SZ:002019) Tianfeng Securities·2025-05-04 10:23Investment Rating - The report maintains a "Buy" rating for the company [4][6][16] Core Views - The company demonstrated strong performance in Q1 2025, with revenue of 1.327 billion yuan, remaining stable year-on-year, and a net profit of 153 million yuan, reflecting a 5% increase [1] - The company's proprietary products are experiencing significant growth, with proprietary product revenue reaching 3.664 billion yuan in 2024, a 50.64% increase year-on-year [2] - The company is focusing on innovation, with two new globally promising products in development, N-3C01 and EY-SF-001, alongside progress in other products [3] Financial Performance - Projected revenues for 2025-2027 are 6.413 billion, 7.201 billion, and 8.305 billion yuan respectively, with net profits expected to be 731 million, 927 million, and 1.103 billion yuan [4][10] - The company is expected to achieve a net profit margin of 11.40% in 2025, increasing to 13.28% by 2027 [11] Market Position - The company has a total market capitalization of approximately 13.794 billion yuan, with a circulating market value of about 9.542 billion yuan [7] - The stock price is currently at 11.34 yuan, with a target price indicating potential upside [6]